The short version of acetylated peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-14. Anything still debated is marked as such rather than presented as settled.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Platelet-Poor Plasma (PPP) is blood plasma with very low number of platelets (< 10 X 103/μL). Traditionally, PPP was recommended for use in platelet aggregation studies to both adjust the platelet-rich plasma concentration, and to serve as a control. PPP may have elevated levels of fibrinogen, which has the ability to form a fibrin-rich clot once activated. Wound healing requires cell migration and attachment, which is facilitated by this fibrin clot.
== Bibliography == Chapple, Christopher Key (1993), Nonviolence to Animals, Earth, and Self in Asian Traditions, State University of New York Press Crane, Eva, ed. (1975). Honey: A Comprehensive Survey. London: Heinemann. ISBN 9780434902705. Crane, Eva (1980). A Book of Honey. New York: Charles Scribner's Sons. ISBN 9780684166513. OCLC 7172738. Jaini, Padmanabh S. (1998) [1979], The Jain Path of Purification, Delhi: Motilal Banarsidass, ISBN 978-81-208-1578-0 Krell, R. (1996). Value-added products from beekeeping. Food and Agriculture Organization of the United Nations. p. 5. ISBN 978-92-5-103819-2. Retrieved 5 January 2016. Root, A. I.; Root, E. R. (2005) [1879]. The ABC and XYZ of Bee Culture. Kessinger Publishing. ISBN 978-1-4179-2427-1. Retrieved 5 January 2016.
Communication delays during the crisis led to the establishment of the Moscow–Washington hotline to allow reliable, direct communications between the two nuclear powers. By the late 1960s, the number of ICBMs and warheads was so high on both sides that it was believed that both the United States and the Soviet Union were capable of completely destroying the infrastructure and a large proportion of the population of the other country. Thus, by some western game theorists, a balance of power system known as mutually assured destruction (or MAD) came into being. It was thought that no full-scale exchange between the powers would result in an outright winner, with at best one side emerging the pyrrhic victor. Thus both sides were deterred from risking the initiation of a direct confrontation, instead being forced to engage in lower-intensity proxy wars. During this decade the People's Republic of China began to build subterranean infrastructure such as the Underground Project 131 following the Sino-Soviet split. One drawback of the MAD doctrine was the possibility of a nuclear war occurring without either side intentionally striking first. Early Warning Systems (EWS) were notoriously error-prone. For example, on 78 occasions in 1979 alone, a "missile display conference" was called to evaluate detections that were "potentially threatening to the North American continent". Some of these were trivial errors and were spotted quickly, but several went to more serious levels.
=== Ubiquitination and role in development === Cereblon forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1), cullin-4A (CUL4A), and regulator of cullins 1 (ROC1). This complex ubiquitinates a number of other proteins and marks them for degradation via the proteasome. Through a mechanism which has not been completely elucidated, this ubiquitination results in reduced levels of fibroblast growth factor 8 (FGF8) and fibroblast growth factor 10 (FGF10). FGF8 in turn regulates a number of developmental processes, such as limb and auditory vesicle formation. The net result is that this ubiquitin ligase complex is important for limb outgrowth in embryos. At the molecular level, C-terminal cyclic imides have been identified as endogenous degrons recognized by cereblon. Cyclic imides can arise through spontaneous peptide-bond cleavage at asparagine or glutamine residues in aging proteins, and have long been observed in proteins such as α-crystallin. In 2022, C-terminal aspartimide and aminoglutarimide residues were shown to bind the thalidomide-binding domain of cereblon and to function as degrons promoting CRBN-dependent ubiquitination and proteasomal degradation. In the absence of cereblon, DDB1 forms a complex with DDB2 that functions as a DNA damage-binding protein. Furthermore, cereblon and DDB2 bind to DDB1 in a competitive manner.
=== Preparation of acyl cyanides === Acyl cyanides (α-oxonitriles) can in certain cases be prepared by reacting carboxylic acid halides with transition metal cyanides (e.g., copper cyanide or silver cyanide). This approach is particularly effective for aromatic carboxylic acid halides and aliphatic acyl bromides, whereas aliphatic acyl chlorides are unreactive. Aliphatic acyl cyanides can instead be synthesized by reacting carboxylic acid chlorides with trimethylsilyl cyanide.
Sources: en.wikipedia.org
Formol titration, invented by the Danish chemist S. P. L. Sørensen in 1907, utilizes formaldehyde in the presence of potassium or sodium hydroxide to measure amino acid concentration and ammonia with the aid of a pH meter. The reagents will also react with proline which can give a slightly higher YAN measurement than NOPA. The formol titration method also has the disadvantages of involving the use and disposal of formaldehyde which is a known carcinogen and the highly toxic reagent barium chloride. Ammonia and ammonium can be measured using an ion-selective electrode and a pH meter.
The southern part of Africa was dominated in the 19th century by a set of struggles to create within it a single unified state. In 1868, Britain annexed Basutoland in the Drakensberg Mountains, following an appeal from Moshoeshoe I, the king of the Sotho people, who sought British protection against the Boers. While the Berlin Conference of 1884–1885 sought to draw boundaries between the European powers' African possessions, it also set the stage for further scrambles. Britain attempted to annex first the South African Republic in 1880, and then, in 1899, both the South African Republic and the Orange Free State. In the 1880s, Bechuanaland (modern Botswana) became the object of a dispute between the Germans to the west, the Boers to the east, and Britain's Cape Colony to the south. Although Bechuanaland had no economic value, the "Missionaries Road" passed through it towards territory farther north. After the Germans annexed Damaraland and Namaqualand (modern Namibia) in 1884, Britain annexed Bechuanaland in 1885. By 1877, the Transvaal government under President Thomas François Burgers was completely bankrupt due to the failed Pedi War and mounting foreign debts. When British official Sir Theophilus Shepstone annexed the republic in April of that year, the state treasury contained only 12 shillings and 6 pence. In the First Boer War of 1880–1881 the Boers of the Transvaal Republic proved skilful fighters in resisting Britain's attempt at annexation, causing a series of British defeats.
=== Pre-structured motifs === Unlike globular proteins, IDPs do not have spatially-disposed active pockets. 80% of target-unbound IDPs (~4 dozens) subjected to detailed structural characterization by NMR possess linear motifs termed PresMos (pre-structured motifs) that are transient secondary structural elements primed for target recognition. In several cases it has been demonstrated that these transient structures become full and stable secondary structures, e.g., helices, upon target binding. Hence, PresMos are the putative active sites in IDPs.
=== Integration of Biocon Biologics === On 6 December 2025, Biocon announced that it would fully integrate its biosimilars subsidiary Biocon Biologics Limited (BBL) as a wholly owned subsidiary, in a corporate action that valued BBL at US$5.5 billion and marked a pivot away from a previously planned initial public offering (IPO) of the biosimilars business. The company said the integration would simplify the group's corporate structure, remove the holding-company discount that had weighed on its valuation, and combine its generics and biosimilars operations into a single listed entity focused on diabetes, oncology and immunology. Under the plan, Biocon acquired the minority stakes held by Serum Institute Life Sciences, Tata Capital Growth Fund II and Activ Pine LLP through a share swap of 70.28 Biocon shares for every 100 BBL shares, priced at ₹405.78 per Biocon share. It also bought out the residual stake held by Mylan Inc. (Viatris) for US$815 million, comprising US$400 million in cash and US$415 million via a share swap, with the swap ratios based on independent valuations by EY. To fund the cash component payable to Viatris, Biocon raised approximately ₹4,150 crore (about US$460 million) through a qualified institutional placement (QIP) completed on 14 January 2026. The integration was completed by 31 March 2026, making Biocon Biologics a wholly owned subsidiary of Biocon Limited and creating a unified entity spanning biosimilars, insulins, generics and peptides. The leadership transition that followed is described under Corporate governance.
=== Statistics === The OECD is known as a statistical agency, as it publishes comparable statistics on numerous subjects. In July 2014, the OECD publicly released its main statistical databases through the OECD Data Portal, an online platform that allows visitors to create custom charts based on official OECD indicators. OECD statistics are available in several forms:
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.